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Abstract
Objectives
Stereotactic body radiotherapy (SBRT) is being increasingly used for the treatment of
patients with lung cancer or lung metastasis who are medically unfit to undergo resection. In
order to improve accuracy and confidence in targeting tumors, many centers rely on fiducial
implantation. We evaluated the migration of a novel fiducial marker specifically designed for
lung tissue implanted via electromagnetic navigation bronchoscopy (ENB).
Methods
We retrospectively quantified the individual and group migrations of SuperLock nitinol coil
fiducials for 15 patients receiving lung stereotactic body radiotherapy (SBRT), in order to
evaluate the reliability of using these fiducials as a target surrogate for cases where tumors
cannot be clearly delineated on cone beam CTs (CBCTs). For each fraction, we compared
the individual and group migrations of the fiducials between the planning CT and the
acquired CBCT. The group migration was defined as the distance between the centroids of
the fiducial group and GTV.
Results
A total of 16 lung targets were included in our study for these 15 patients (one patient with
two targets). Of 55 fiducials placed, we observed a 100% retention rate. The mean individ-
ual migration was 1.87 mm (range, 0.63–5.25 mm) with a standard deviation of 1.26 mm.
The mean group migration was 1.94 mm (range, 0.03–6.19 mm) with a standard deviation
of 1.45 mm. Overall, there was minimal change in the relative locations of the markers with
respect to each other, as well as to the target.
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Conclusions
We found that the SuperLock nitinol coil fiducial marker positions are stable throughout the
radiation treatment, and can be used as a reliable surrogate to target, and to avoid geomet-
ric misses during gated treatments.
Introduction
In the modern era of image guided radiotherapy (IGRT), techniques that seek to further refine
the accuracy of treatment delivery have become a highly researched topic. Advancements in
areas such as patient immobilization, image acquisition, as well as target localization have con-
tributed to a substantial reduction in both inter- and intrafraction variation, allowing for more
consistent and accurate treatment [1,2]. One of the most widely investigated applications of
IGRT involves the management of respiration-induced organ motion. Early studies examining
lung and liver movement during the respiratory cycle through the use of implanted fiducial
surrogate-based real-time tracking, fluoroscopy, and 4D computed tomography (4DCT) dem-
onstrated organ motion of up to 2 to 3 cm, particularly in the cranial-caudal dimension [3–9].
Similar motion has been observed for upper abdominal organs. For example, pancreas motion
up to 2–4 cm has been reported based on ultrasound measurements [10].
Respiratory motion affects most thoracic and abdominal tumor sites when treating with
radiation, including lung cancer. In the United States alone, primary lung malignancies consti-
tute 50–60% of most new invasive cancers [11]. Non-small cell lung cancers (NSCLC) account
for 80–85% of these cases, with 10–15% falling into the category of early-stage, localized dis-
ease. For patients diagnosed with early stage, medically-inoperable NSCLC, stereotactic body
radiotherapy (SBRT) has brought promising results, yielding low local recurrence rates ranging
from 3% to 20% [12–16]. SBRT, also known as stereotactic ablative radiation therapy (SABR),
delivers a high dose per fraction to an extra-cranial target in a small number of fractions [17].
In addition to the high dose ablating the tumor cells, recent advances in radiation therapy
physics enable a steep dose gradient outside the tumor for limited normal tissue damage, thus
optimizing the therapeutic ratio [13].
Given widespread acceptance of SBRT in the management of early-stage inoperable NSCLC
(as well as the increasingly common use of SBRT in oligometastatic disease), there has been an
increasing focus on technologies that allow for tumor tracking with respiratory motion, in
order to further reduce the normal tissue damage by minimizing treatment margins required
for a moving target [1–3]. During an SBRT treatment, a challenge is the absence of high radi-
opaque contrast in 2D radiographic imaging for pulmonary lesions [18]. It has been reported
that it is difficult to visualize lung tumors smaller than 2.4 cm using 2D radiographic or fluoro-
scopic images [19]. Such situations may benefit from bronchoscopically-implanted fiducial
markers near the tumor to improve tumor localization. The usefulness of such markers, how-
ever, can be negated by their potential migration [18,20,21]. The potential for fiducial migra-
tion over the course of treatment is a recognized drawback to this method that could result in
inaccurate dosing to the tumor and surrounding tissues. The SuperLock (Covidien, Inc.,
Minneapolis, MN, USA) gold fiducial marker was specifically designed with a nitinol wire to
minimize migration in the lung tissue. The primary objective of the present study is to retro-
spectively quantify the individual and group migration of SuperLock nitinol coil fiducial mark-
ers for patients receiving lung SBRT, thereby evaluating the reliability of using these fiducials
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as a target surrogate in specific cases where tumors cannot be clearly delineated on cone beam
CT (CBCT).
Material and Methods
Ethics statement
The study was approved by the Ohio State University Cancer Institutional Review Board (IRB,
2014C0070). Patient records were anonymized prior to analysis. Patient consent was not
required since this was a retrospective study with full waiver.
Patient characteristics
A total of fifteen consecutive patients treated with gated SBRT between 2012 and 2014 with pri-
mary NSCLC and lung oligometastases were included in the study. The 15 patients underwent
15 simulation CTs and 58 CBCTs. All of these patients received SBRT with breath-hold gated
treatment for a total of 45–55 Gy in 3–5 fractions. Patient demographic information is listed in
Table 1. Patient age at treatment initiation ranged from 49 to 82 years old. Tumor size ranged
from 0.8 to 3.6 cm in diameter, based on the most recent CT or PET/CT prior to treatment.
Patient #7 had two lesions, one in the left lung, and another in the right lung. Therefore, a total
of 16 target lesions were studied and analyzed.
Fiducial marker placement
The SuperLock nitinol coil fiducial markers were used for all exhale breath-hold gated lung
SBRT treatments. As shown in Fig 1, these fiducials are made of a 0.8 mm x 3.5 mm textured
gold seed attached to a coiled nitinol wire, for an overall length of 7 mm. The seed was designed
to minimize migration in the lung parenchyma, and appeared as radiopaque seeds on fluoro-
scopic imaging. Patients were identified at the time of physician consultation to see if they were
appropriate candidates for the breath-hold gated SBRT protocol. All patients who consented to
Table 1. Patients’ characteristics.
# Sex Age * Diagnosis Location Tumor Size (cm) ⁿ Dose/Fractionation
1 M 81 urothelial carcinoma LUL 3.6 50 Gy in 4 fractions
2 F 72 NSCLC (stage IA) LLL 1.6 54 Gy in 3 fractions
3 M 69 colorectal adenocarcinoma RUL 1.1 51 Gy in 3 fractions
4 M 49 colorectal adenocarcinoma LLL 0.8 54 Gy in 3 fractions
5 F 64 colorectal adenocarcinoma RLL 0.9 55 Gy in 5 fractions
6 M 62 NSCLC (stage IV), progressive nodule RUL 2.5 50 Gy in 4 fractions
7 F 82 colorectal adenocarcinoma LLL; RUL 1.8; 3.5 50 Gy in 4 fractions (both)
8 F 78 NSCLC (stage IV), progressive nodule RLL 1.6 45 Gy in 3 fractions
9 F 71 colorectal adenocarcinoma RLL 1.8 51 Gy in 3 fractions
10 M 63 NSCLC (stage IA) RUL 1.4 54 Gy in 3 fractions
11 F 51 colorectal adenocarcinoma LLL 3.2 55 Gy in 5 fractions
12 M 73 NSCLC (stage IB) RLL 3.3 48 Gy in 4 fractions
13 M 76 NSCLC (stage IA) RUL 2.1 50 Gy in 5 fractions
14 F 72 colorectal adenocarcinoma LLL 1.1 54 Gy in 3 fractions
15 M 76 NSCLC (stage IA) RLL 1.3 50 Gy in 4 fractions
* = age at tx initiation
ⁿ = based on most recent CT or PET/CT prior to tx
doi:10.1371/journal.pone.0131945.t001
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receive this treatment were referred to pulmonary or thoracic surgery for placement of Super-
Lock nitinol coil fiducials (n = 3 or 4) adjacent to their lung lesions (typically within 2 cm). The
fiducial placement was performed through a minimally invasive electromagnetic navigated
bronchoscopy procedure using the superDimension Navigation System (Covidien, Inc., Min-
neapolis, MN, USA). A mobile fluoroscopic C-Arm system (GE Healthcare, Waukesha, WI,
USA) was used to monitor and confirm the fiducial placement, as shown in Fig 2. Patients
were CT simulated no sooner than 40–48 hours after fiducial implantation.
CT simulation and treatment planning
Our CT simulation protocol for lung SBRT breath-hold gated treatment included two steps: A
4D-CT scan followed by a standard planning CT scan with or without intravenous contrast.
The 4D-CT scan was performed with abdominal compression (CIVCOMedical Solutions,
Coralville, Iowa, USA) to determine the maximum tumor motion, which was then used to
determine the type of planning CT scan (a free-breathing scan if the motion was 1 cm, or a
breath-hold scan otherwise). If the tumor motion was larger than 1 cm, Respiratory Position
Management (RPM, Varian Medical Systems, Palo Alto, CA, USA) was used to record the
breath-hold level. Accordingly, patients were treated with a breath-hold gated SBRT technique.
For this treatment, the target contour was the gross tumor volume (GTV) on the breath-hold
Fig 1. The SuperLock nitinol coil fiducial marker.
doi:10.1371/journal.pone.0131945.g001
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CT, with recommended minimum 5 mm axial and 5–8 mm superior-inferior margins to gener-
ate the planning target volume (PTV). The variation in the superior-inferior margin depended
on the tumor motion magnitude, 4D CT quality, and physician preference. A variety of treat-
ment planning techniques, including 3D conformal treatment, intensity modulated radiother-
apy (IMRT), or dynamic conformal arc therapy, were considered for the optimal dosimetric
conformity, rapid dose fall-off, as well as faster delivery time. Treatments were delivery through
a Varian TrueBeam Linac (Varian Medical Systems, Palo Alto, CA, USA), with the 6X flatten-
ing-filter-free beam and 1000 MU/min dose rate.
Treatment procedure and imaging protocol
Median interval between the planning CT and the first CBCT was 2 weeks. Subsequent CBCTs
were taken at 1–2 day intervals, except during the weekend, with the goal of delivering 2–3 frac-
tions per week. During each fraction of SBRT, the pre-treatment imaging sequence included at
least one kilovoltage (kV) CBCT, which was acquired in the “Spotlight” mode with manual gat-
ing, as shown in Fig 3. Therapists started CBCT acquisition after the breath-hold trace settled
in the gating window and stopped it before instructing patients to breath freely. It typically
required 2–3 breath-holds to reconstruct a full Spotlight CBCT. In addition, 2D breath-hold
kV-kV pair (2D-pair for short) images were used for bony anatomy alignment and 2D marker
Fig 2. SuperLock nitinol coil fiducials deployed into the left lower lobe of the lung through
electromagnetic navigation bronchoscopy. Five fiducials were deployed, four in or within 1–2 cm of the
tumor, and one further away as visualized during the placement procedure (panel A), and at a post-procedure
chest radiograph (panel B). The fiducials were centered around the tumor, which is not well-visualized in the
kV images.
doi:10.1371/journal.pone.0131945.g002
Fig 3. Breath-hold CT and CBCT (spotlight) matching with three fiducial markers in the left lower lobe
of the lung, just prior to SBRT treatment. Panel A shows CBCT completely overlaid onto the planning CT
images. Panel B-C shows the two-way sliding windowmatching between CBCT and planning CT images.
doi:10.1371/journal.pone.0131945.g003
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matching prior to or after the CBCT, as shown in Fig 4. Both fiducial registration and bony
anatomy registration were considered and the final shift would take into account both and split
the difference if they were not consistent. Within our study group, 11 out of 15 patients were
imaged with a 2D-pair followed by a breath-hold CBCT. After the initial 2D-pair alignment,
each patient was further aligned with the registration between the breath-hold CBCT and the
planning CT. This latter alignment served as the primary registration and provided the final
shifts prior to treatment. Patients 3 and 5 on the list were imaged with a breath-hold CBCT
first followed by a 2D-pair, and patients 4 and 10 were imaged with a breath-hold CBCT only.
This procedural variation depended solely on the attending physician’s preference. The CBCT
scans were rigidly registered to the planning CT by minimizing the differences in fiducial loca-
tions, bony anatomy and target positioning in order to achieve the optimal fusion. Even with
RPMmonitoring, the breath-hold level can still vary significantly. Therefore, we typically per-
formed a second series of breath hold gated imaging if the shifts were considered too large
(greater than 3 mm), in order to confirm the shifts. Table positions were re-acquired after the
first fraction imaging.
Data acquisition and analysis
There were a total of 55 fiducials and 16 tumor targets. For each fraction, we compared the
individual and group migrations of the fiducials between the post-implantation planning CT
and the acquired CBCT for each fraction. The individual migration was defined as the averaged
relative distance of each individual fiducial between the planning CT and the subsequent
CBCTs. In other words, the migration of each fiducial was calculated based on the 3D coordi-
nates on CBCTs with respect to its location in the planning CT. Therefore, the accuracy of
CT-CBCT registration is essential for the individual migrations. The group migration was
defined as the distance between the centroids of the fiducial group and the GTV. GTVs were
contoured on the planning CTs and CBCTs in order to locate the geometric centers of the tar-
get. The group migration of each set of 3–4 fiducials was calculated based on the difference in
fiducial-to-GTV centroid distances between the planning CT and the subsequent CBCTs. The
fiducial-to-GTV centroid distance was calculated based on the 3D coordinates of the fiducial
group centroid with respect to the GTV center on each CBCT.
Fig 4. Position of three SuperLock nitinol coil fiducials used in two dimensional (2D) marker matching
just prior to SBRT treatment for a left lower lobe lung tumor as visualized using on-board kV imaging
(panel A: anterior-posterior image; panel B: lateral image). Three green crosses showed locations of the
fiducials identified from the planning CT. The background images were 2D kV-kV pair images acquired prior
to treatment.
doi:10.1371/journal.pone.0131945.g004
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Results
For the 15 patients undergoing SBRT in this study, the median number of SBRT fractions was
3, and the median number of fiducials placed in or near the tumor was 3. All fiducials
implanted were readily visible on planning CT imaging, as well as the kV and CBCT images
acquired on the day of treatment, reflecting a 100% retention rate. To enable the marker
matching function on the Varian TrueBeam system, fiducials needed to be identified on the
treatment planning system, as shown in Fig 5. As shown on Figs 3 and 5, there were low-degree
streaky artifacts introduced by the fiducials on the CBCT images. Despite these artifacts, we
found that the optimal visualization of the target on the CBCT was better when the fiducials
were near the target, but not directly residing in it. For each fraction, we compared individual
and group migrations of the fiducials between the planning CT and CBCTs. Between fractions,
as shown in Table 2, the mean individual migration was 1.87 mm (range, 0.63–5.25 mm) with
a standard deviation of 1.26 mm. The mean group migration was 1.94 mm (range, 0.03–6.19
mm) with a standard deviation of 1.45 mm. Overall, the majority of the fiducial markers had
relative location changes of less than 5 mm. Figs 6 and 7 depict the group and averaged individ-
ual migrations for each target, respectively. Fig 6 shows the fiducial group migration for each
fraction by target lesion, while Fig 7 shows average individual migration across all the fractions
for each fiducial placed around a target lesion. Except for two patients (Target 8 and 10, Figs 6
and 7), the majority of the observed migrations were below 4 mm. Taking into account the
measurement uncertainty inherent with the CBCT image quality and object smearing out with
respiratory motion, we concluded this amount of migration is within our accepted tolerance
based on the minimum PTV expansion of 5 mm. Fig 8 plots the shifts after the first imaging
Fig 5. CBCT images of 4 fiducials placed in or near a tumor in the right upper lobe treated with SBRT
in (A) axial, (B) frontal, and (C) sagittal views. The four green squares indicated the four fiducials identified
on the planning CT.
doi:10.1371/journal.pone.0131945.g005
Table 2. Maximum, mean, and standard deviation for fiducial individual and groupmigration.
Total Fiducials 55
Total Targets 16
Total Patients 15
Individual Migration (mm)
Max 5.25
Min 0.63
Mean 1.87
Stdev 1.26
Group Migration (mm)
Max 6.19
Min 0.03
Mean 1.94
Stdev 1.45
doi:10.1371/journal.pone.0131945.t002
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sequence (residual shifts) in the vector of all three directions across fractions for each target. As
we mentioned previously, the majority of patients (11 out of 15) were imaged with 2D-pair fol-
lowed by breath-hold CBCT. The shift adjustments made from 2D-pair were based on bony
anatomy alignment and marker-marker matching in or around the target. As shown in Fig 8,
the residual shifts indicated from the breath-hold CBCT were mostly within 6 mm (the vector
of all three directions), after adjusting the patient’s positioning based on a 2D-pair for those 11
patients. The remaining patients (4/15) were imaged either with the breath-hold CBCT first
followed by 2D kV pair (2), or with the breath-hold CBCT only (2). These four patients with
the different imaging sequence or lack of 2D-pair were the ones with the largest shifts on the
first fraction as indicated in Fig 8. Despite this, there is likely no clinical impact with these large
shifts for these four patients, since the shifts were applied subsequently to correct for any setup
misalignments. However, an additional gated imaging may be necessary for these patients in
order to confirm the reproducibility of the imaging position.
Fig 6. Fiducial groupmigration with respect to the GTV for all 16 targets.
doi:10.1371/journal.pone.0131945.g006
Fig 7. Fiducial averaged individual migration with respect to the planning CT for all 16 targets.
doi:10.1371/journal.pone.0131945.g007
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Discussion
Pulmonary tumor motion is a significant problem both during and between SBRT treatments.
Fiducials serve as one way to mitigate the effects of motion by allowing for improved IGRT. In
this study, we have examined the migration of the grouped and individual intrapulmonary
SuperLock nitinol coil fiducials centered around the SBRT target, in order to evaluate marker
stability within the pulmonary parenchyma. Given the less dense nature of pulmonary tissue
(typically ~1/3rd dense compared with other soft tissues that commonly use fiducial markers
for SBRT including liver and prostate), there is a real concern that fiducial markers migrate in
lung tissue more than other organ sites. To our knowledge, this is the first study assessing
potential marker migration of the SuperLock nitinol coil fiducials, which have been designed
specifically for lung tissue.
Overall, we observed the majority of fiducial migrations to be less than 5 mm. The mean
migrations for individual and group markers were both under 2 mm, and the standard devia-
tions for the individual and group markers were under 2 mm as well. As fraction number
increased, we did not find substantial or consistent changes in the group inter-marker migra-
tions (Fig 6), suggesting that radiation did not result in significant organ-tissue deformation
during the course of treatment. These results may have implications for correctly targeting
lung tumors using these implanted fiducial markers. This study is a single center retrospective
study with 15 patients/16 tumors included, and the authors realize that this may not be neces-
sarily representative of a much larger population of patients. However, the use of the three fidu-
cial combination may enhance the accuracy of treatment over single fiducial alignment, by
avoiding issues of organ deformation (which we did not detect in this study). Indeed, other
studies have demonstrated that more than a single fiducial improves target localization [22].
Prior to the introduction of this new SuperLock nitinol coil fiducial marker, commonly
used fiducial markers for pulmonary tumors include “seed” and “coil”markers [20,21,23–27].
These commercially-available markers have various shapes (sphere [20,25] or cylindrical
[21,23,24,26,27]) and sizes (1.5 mm–2 cm). In terms of the retention rate, the present study
reports a 100% rate for these nitinol coil markers, which is equivalent or superior to other
marker shapes (close to 100% for the coil markers [23,24] and 85–95% for the sphere marker
[23–25]). In terms of the rate and extent of marker migration, previous studies have observed a
rate of 12% of markers experiencing large migrations (>5 mm) for both seed and coil markers
[21,23,25]. The present study noted a 7% rate of the fiducial markers having a>5 mm
Fig 8. Residual shifts after the first imaging prior to the SBRT treatment for all 16 targets.
doi:10.1371/journal.pone.0131945.g008
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migration. A follow-up study with a larger population of patients is necessary to further estab-
lish the stability of these fiducial markers.
As shown in Fig 8, alignment based on the three fiducial’s group geometric center should
provide a very reasonable alignment of the lung tumor within the radiation field/isocenter,
which was confirmed by the residual shifts observed from the breath-hold CBCT-to-CT soft
tissue matching just prior to treatment. This finding indicates that in the absence of CT-CBCT
matching, the intrapulmonary implanted fiducials should still allow for a reliable and simple
localization approach for treatment of the lung tumor. However, if both 2D-pair and CBCT
imaging techniques are available, the sequence of 2D-pair followed by CBCT is recommended
based on our findings. This imaging sequence largely decreases the residual shifts after the first
imaging, which minimizes the variations inherent in a breath-hold imaging acquisition and
provides improved confidence in patient positioning. In our study, the four patients who
received CBCT first or CBCT only had the largest residual shifts, which indicated that an addi-
tional imaging may be necessary in order to confirm the reproducibility of the imaging posi-
tion. This could subsequently increase patient’s discomfort by requiring additional breath-
holds, thereby prolonging total treatment time. Respiratory-gated treatments can also be facili-
tated by monitoring the fiducial motion during the breathing cycle, using MV or kV fluoro-
scopic or cine-mode imaging prior to and/or during treatment. Given that re-irradiation is
being considered more frequently in the setting of recurrent lung cancer [28–30], fiducial
based SBRT approaches may become more common, which allow for decreased volumes of
normal lung irradiated and decreased overlap from prior treatment fields.
Fiducial placement via CT guidance is typically associated with a high rate (from 13% [5] to
over 60% [31–33]) of iatrogenic pneumothorax. All of the fiducials in this study were placed by
electromagnetic navigation bronchoscopy (ENB) [34,35]. While fiducials are likely to aid with
target localization and enhance accurate treatment delivery, the implantation of fiducials is not
without potential risks of toxicity. In addition to the implantation procedure carrying its own
set of risks, a number of case reports have also been published describing dislodgement or
migration of fiducials, sometimes with significant clinical consequences [36–38]. Thus, patients
need to be aware of these risks associated with the implantation and use of fiducials, and physi-
cians need to weigh these risks compared with the benefits of improved accuracy with these
markers for SBRT. One potential way to avoid additional risks and minimize more procedures
are to have fiducials implanted at the time of a diagnostic biopsy of a pulmonary nodule or
mass, particularly if the physician performing the procedure deems the patient a potential can-
didate for SBRT (e.g. medically inoperable).
In summary, we have demonstrated that the SuperLock nitinol coil fiducial markers demon-
strated minimal migration or displacement from the time of treatment planning through treat-
ment delivery in patients receiving lung SBRT. These fiducials also retained their relative
position to the tumor throughout the course of SBRT. Fiducial implantation helps to improve
the efficiency and accuracy of patient positioning through 2D-pair imaging and marker match-
ing techniques. To our knowledge, this is the first report characterizing migration of these par-
ticular fiducials in lung tissue. Thus, SuperLock nitinol coil fiducials are reliable surrogates in
cases where the target is not clearly visualized on the planning CT and/or CBCT, and will serve
as appropriate markers for real-time tracking or gated SBRT techniques to enhance treatment
delivery.
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